Here, we identified a new mutant Δ133p53α-specific pathway in which it increases IDO1 (indoleamine-2,3-dioxygenase 1) and IL4I1 (interleukin-4 induced 1) expression and activates AHR (aryl hydrocarbon receptor), a tumor-promoting mechanism. Here, IDO1 is linked to neoplasm.